Recently, Denosumab (Prolia), a fully humanized anti-RANKL monoclonal antibody, has been approved by the FDA to treat osteoporosis8 and bone loss in patients with prostate or breast cancer undergoing hormone ablation therapy9. This evidence concerns the gene TNFSF11 and breast cancer.